IndraLab

Statements

USP14 inhibits Multiple Myeloma. 2 / 2
| 2
reach
"USP14 and UCHL5 short interfering RNA knockdown decreases MM cell viability."
24319254
reach
"The USP14/ubiquitin C-terminal hydrolase L5 (UCHL5) inhibitor VLX1570 was reported to inhibit multiple myeloma (MM) progression in vivo [145]; unfortunately, a phase I/II clinical trial (NCT02372240) evaluating the safety and efficacy of VLX1570 and dexamethasone in patients with refractory MM was terminated due to intolerable toxicity [146]."
38715050